SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dickinson Andrew D
(Last) (First) (Middle)
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
(Street)
FOSTER CITY CA 94404
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/29/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/29/2024 M(1) 18,630 A $73.77 157,549 D
Common Stock 11/29/2024 M(1) 26,170 A $57.92 183,719 D
Common Stock 11/29/2024 M(1) 33,660 A $68.75 217,379 D
Common Stock 11/29/2024 M(1) 60,885 A $71.91 278,264 D
Common Stock 11/29/2024 M(1) 43,340 A $72.7 321,604 D
Common Stock 11/29/2024 M(1) 65,960 A $72.7 387,564 D
Common Stock 11/29/2024 S(1) 120,715 D $92.7652(2) 266,849 D
Common Stock 11/29/2024 S(1) 127,930 D $92.7626(3) 138,919 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Option (Right to Buy) $57.92 11/29/2024 M(1) 26,170 (4) 03/10/2032 Common Stock 26,170 $0 130,860 D
Non-qualified Stock Option (Right to Buy) $73.77 11/29/2024 M(1) 18,630 (5) 11/10/2027 Common Stock 18,630 $0 0 D
Non-qualified Stock Option (Right to Buy) $68.75 11/29/2024 M(1) 33,660 (4) 02/06/2029 Common Stock 33,660 $0 0 D
Non-qualified Stock Option (Right to Buy) $71.91 11/29/2024 M(1) 60,885 (4) 06/10/2028 Common Stock 60,885 $0 0 D
Non-qualified Stock Option (Right to Buy) $72.7 11/29/2024 M(1) 43,340 (5) 08/10/2027 Common Stock 43,340 $0 0 D
Non-qualified Stock Option (Right to Buy) $72.7 11/29/2024 M(1) 65,960 (4) 12/10/2026 Common Stock 65,960 $0 0 D
Explanation of Responses:
1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
2. Sales prices reported for the transactions reported here range from $92.36 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
3. Sales prices reported for the transactions reported here range from $92.33 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
4. The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
5. The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested.
/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson 12/03/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Gilead Sciences (NASDAQ:GILD)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Gilead Sciences.
Gilead Sciences (NASDAQ:GILD)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Gilead Sciences.